{
    "Trade/Device Name(s)": [
        "TEG 6s Hemostasis System",
        "TEG 6s Citrated: K, RT, FF Assay Cartridge",
        "TEG 6s Hemostasis Analyzer"
    ],
    "Submitter Information": "Haemonetics Corporation",
    "510(k) Number": "K183160",
    "Predicate Device Reference 510(k) Number(s)": [
        "K993678",
        "K002177"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JPA",
        "GGN"
    ],
    "Summary Letter Date": "May 9, 2019",
    "Summary Letter Received Date": "November 15, 2018",
    "Submission Date": "November 14, 2018",
    "Regulation Number(s)": [
        "21 CFR 864.5425"
    ],
    "Regulation Name(s)": [
        "Multipurpose system for in vitro coagulation studies"
    ],
    "Analyte Class(es)": [
        "coagulation",
        "hematology"
    ],
    "Analyte(s)": [
        "Clotting Time (R)",
        "Maximum Clot Strength (MA)",
        "Fibrinolysis after 30 minutes (LY30)",
        "Fibrinogen",
        "Platelets",
        "Kaolin-activated parameters",
        "Tissue Factor-activated parameters"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [
        "3.2% sodium citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "TEG 6s Hemostasis Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Thromboelastography",
        "Optical resonance frequency measurement",
        "Microfluidic assay cartridge"
    ],
    "Methodologies": [
        "Thromboelastography",
        "In vitro viscoelastic testing"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Assay Cartridge",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for the TEG 6s Hemostasis System and Citrated: K, RT, FF Assay Cartridge for assessment of coagulation properties in whole blood using thromboelastography.",
    "Indications for Use Summary": "Intended for in vitro diagnostic use in adult patients (18+ years) to assess blood hemostasis properties in trauma settings, aiding evaluation of hemorrhage or thrombosis with three assays (CK, CRT, CFF) analyzing clotting time, strength, and fibrinolysis in 3.2% citrated whole blood.",
    "fda_folder": "Hematology"
}